Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Cash from Investing Activities: 2016-2025

Historic Cash from Investing Activities for Sunshine Biopharma (SBFM) over the last 6 years, with Sep 2025 value amounting to -$118,295.

  • Sunshine Biopharma's Cash from Investing Activities rose 82.36% to -$118,295 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.2 million, marking a year-over-year increase of 43.03%. This contributed to the annual value of -$2.3 million for FY2024, which is 253.71% down from last year.
  • Per Sunshine Biopharma's latest filing, its Cash from Investing Activities stood at -$118,295 for Q3 2025, which was up 75.95% from -$491,778 recorded in Q2 2025.
  • Sunshine Biopharma's Cash from Investing Activities' 5-year high stood at $18,859 during Q3 2023, with a 5-year trough of -$14.6 million in Q4 2022.
  • Its 3-year average for Cash from Investing Activities is -$342,099, with a median of -$269,230 in 2023.
  • Per our database at Business Quant, Sunshine Biopharma's Cash from Investing Activities spiked by 98.16% in 2023 and then slumped by 3,655.86% in 2024.
  • Quarterly analysis of 4 years shows Sunshine Biopharma's Cash from Investing Activities stood at -$14.6 million in 2022, then surged by 98.16% to -$269,230 in 2023, then plummeted by 63.17% to -$439,304 in 2024, then surged by 82.36% to -$118,295 in 2025.
  • Its last three reported values are -$118,295 in Q3 2025, -$491,778 for Q2 2025, and -$176,024 during Q1 2025.